Sponsored · Webinar
Sept. 15 – Challenges of Implementing Innovation in Drug Discovery & Development
Phenotypic Screening & Profiling to Understand a Compound’s Disease Impact
While you missed the live webinar, you can still watch a recording by following the link below.
Learn how diverse drug development companies with unique models of discovery, innovative drug modalities, and non-traditional/natural product source material use phenotypic screening and profiling to understand their compounds’ disease impact.
The measurement of multiple biological activities following drug treatment of cell-based systems, a central tenant of phenotypic screening and profiling, is experiencing a renaissance in drug discovery as companies look beyond biochemical approaches to complex cell and tissue systems with high physiological relevance. Previously, challenges of data interpretation and limited data analytics, unclear relevance or benefit to human disease, and lack of throughput and leadership support for this approach hindered broad adoption. Many of these issues now have robust data-rich solutions, and leading scientists are reaping the benefits of an activity profiling approach.
Date: Tuesday, Sept. 15, 2020
Time: 9:00am PDT / 12:00pm EDT
Duration: 1 hour
- Alison O’Mahony – Vice President, Translational Biology, Eurofins Discovery
- Lisa Schopf – Senior Director, Pfizer
- Stephanie Venn-Watson – Co-Founder, Chief Executive Officer, Epitracker
- Kieron Edwards – Chief Scientific Officer, Sibelius